Australia markets open in 7 hours 28 minutes

HTG MOLECUL.DIAGN.DL-,001 (65HA.MU)

Munich - Munich Delayed price. Currency in EUR
Add to watchlist
3.1800-0.1000 (-3.05%)
As of 8:02AM CEST. Market open.
Full screen
Previous close3.2800
Open3.1800
Bid2.9400 x N/A
Ask3.0000 x N/A
Day's range3.1800 - 3.1800
52-week range3.1800 - 10.8959
Volume266
Avg. volume9
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • HTG Molecular Diagnostics Reports First Quarter 2021 Results and Provides a Corporate Update
    GlobeNewswire

    HTG Molecular Diagnostics Reports First Quarter 2021 Results and Provides a Corporate Update

    Call scheduled for today, May 13, at 4:30 pm ETTUCSON, Ariz., May 13, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the first quarter ended March 31, 2021. Recent Business Highlights ● Released a second technical white paper (White Paper Two) characterizing the company’s planned transcriptome panel using the HTG EdgeSeq technology. White Paper Two, among other things, compares the performance and feasibility of a prototype of HTG’s planned transcriptome panel to RNA sequencing (RNA-Seq) across multiple cancer indications. White Paper Two also demonstrates the feasibility and expected performance of the transcriptome panel, including: ○ Ability to differentiate samples based on gene expression profiles;○ Repeatability amongst replicates from multiple cancer indications with archived samples;○ Accuracy of differential expression analysis using a direct comparison to RNA-Seq;○ Potential as a robust alternative to RNA-Seq for gene expression profiling while maintaining the advantages of the HTG EdgeSeq technology. With the feasibility testing for all elements of the panel’s design complete, the company is now in the optimization phase of development, working to further improve the panel’s design, workflow, and robustness. Having completed our final round of probe quality control testing, defined our quality control metric strategy and finalized the reagent formulation during the quarter, we have ordered our final probe pool for the panel. Final panel design lock is anticipated in the second quarter of 2021 followed by formal panel design verification with initial commercialization anticipated by the third quarter of 2021. ● Increased participation in the company’s transcriptome panel Early Adopter Program (EAP), refining study details with over 25 collaborators to date, including those in both academia and pharma. The EAP allows a select group of customers access to the initial transcriptome panel for use in their laboratories or through services performed by HTG prior to commercial launch of the panel. “Our team continues to be very optimistic about the launch of the transcriptome panel using our HTG EdgeSeq technology,” said John Lubniewski, President and CEO of HTG. “Data published in our second white paper highlight the potential of this panel as a robust, clinically deployable alternative to RNA-Seq for gene expression profiling. We believe the benefits of our HTG EdgeSeq technology and the transcriptome panel, including ease of use, cost savings, turnaround time and broad applicability, will make this a very attractive alternative for gene expression profiling applications. We continue to meet our development milestones and look forward to providing updates on our progress in the coming months.” “In the fourth quarter of 2020, our base business showed signs of recovery after experiencing a substantial impact from COVID-19 in the second and third quarters of 2020. The reopening process stalled again in the first quarter of 2021 in Europe and our pharmaceutical company customers have continued a slow return to pre-COVID-19 clinical trial levels. We are hopeful of a return to pre-COVID revenue levels as vaccinations become more widely available and business continues to normalize,” Mr. Lubniewski continued. First Quarter 2021 Financial Highlights: Total revenue for the first quarter ended March 31, 2021 was $1.4 million, compared with $2.2 million for the same period in 2020. HTG believes the decrease in revenue is a result of the impact of the COVID-19 pandemic requiring the closure of customer facilities, causing a significant reduction in oncology-related clinical trial activity or limiting the ability of our customers to operate at pre-pandemic levels. Product and product-related services revenue was $1.4 million, compared with $2.0 million for the same period in 2020. Throughout the pandemic, HTG’s ability to ship instruments and consumables to customer facilities and the ability of its customers to prepare and ship samples to HTG’s VERI/O laboratory for processing has been limited. There was no collaborative development services revenue for the quarter ended March 31, 2021, compared with $0.2 million for the same period in 2020, reflecting the completion of remaining tasks under existing arrangements. The company has ongoing sales efforts to identify and contract new programs in this area. Net loss from operations for the first quarter ended March 31, 2021 was $4.6 million, compared with $5.4 million for the same period in 2020. Net loss per share was $(0.80) for the quarter ended March 31, 2021 compared with $(1.27) for the same period in 2020. Cash, cash equivalents and short-term available-for-sale securities totaled $30.8 million as of March 31, 2021, with current liabilities of approximately $8.3 million and non-current liabilities of $11.5 million. Conference Call and Webcast: HTG will host a conference call for the investment community today beginning at 4:30 p.m. Eastern Time. Conference call and webcast details are as follows: Date: Thursday, May 13, 2021Time: 4:30 p.m. Eastern TimeToll Free: (877) 407-0789International: (201) 689-8562Conference ID: 13719223Webcast: http://public.viavid.com/index.php?id=144644 About HTG:HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine. Safe Harbor Statement: Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated performance characteristics and benefits of our planned transcriptome panel, the related Early Access Program, the impact of strategic adjustments made to lessen the impact of COVID-19, our belief that direct revenue from our core oncology business will begin to recover to pre-COVID levels, and the expected timing of the commercial launch of our transcriptome panel. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with the impact of the COVID-19 pandemic on us and our customers; the risk that our transcriptome panel may not provide the benefits that we expect; risks associated with our ability to develop and commercialize our products, including our transcriptome panel; the risk that our products and services may not be adopted by biopharmaceutical companies or other customers as anticipated, or at all; our ability to manufacture our products to meet demand; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Quarterly Report on Form 10-Q for the period ended March 31, 2021. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Contact: Ashley RobinsonPhone: (617) 430-7577Email: arr@lifesciadvisors.com -Financial tables follow- HTG Molecular Diagnostics, Inc. Consolidated Statements of Operations Three Months Ended March 31, 2021 2020 Revenue: Product and product-related services $1,435,146 $1,988,137 Collaborative development services — 237,337 Total revenue 1,435,146 2,225,474 Operating expenses: Cost of product and product-related services revenue 785,200 1,015,492 Selling, general and administrative 3,859,619 4,675,263 Research and development 1,372,040 1,926,275 Total operating expenses 6,016,859 7,617,030 Operating loss (4,581,713) (5,391,556)Other income (expense), net (264,145) (61,166)Net loss before income taxes (4,845,858) (5,452,722)Provision for income taxes (2,449) (5,176)Net loss $(4,848,307) $(5,457,898) Net loss per share, basic and diluted $(0.80) $(1.27)Shares used in computing net loss per share, basic and diluted 6,040,752 4,304,529 HTG Molecular Diagnostics, Inc. Consolidated Balance Sheets March 31, December 31, 2021 2020 Assets Current assets: Cash and cash equivalents $21,777,687 $22,397,812 Short-term investments available-for-sale, at fair value 8,987,844 6,298,075 Accounts receivable 1,250,048 1,588,767 Inventory, net 1,602,874 1,492,126 Prepaid expenses and other 1,530,203 1,094,273 Total current assets 35,148,656 32,871,053 Operating lease right-of-use assets 349,074 1,009,097 Property and equipment, net 1,124,258 1,227,402 Other non-current assets 5,853 90,356 Total assets $36,627,841 $35,197,908 Liabilities and stockholders' equity Current liabilities: Accounts payable $1,352,837 $1,348,762 Accrued liabilities 1,114,810 1,459,878 Contract liabilities - current 493,869 185,083 NuvoGen obligation - current 479,403 512,729 Current portion of long-term debt 4,501,741 3,022,139 Operating lease liabilities - current 373,946 685,220 Other current liabilities 20,293 22,563 Total current liabilities 8,336,899 7,236,374 NuvoGen obligation - non-current, net of discount 4,354,839 4,479,396 Long-term debt, net 7,046,617 8,568,308 Operating lease liabilities - non-current — 368,682 Other non-current liabilities 49,424 60,488 Total liabilities 19,787,779 20,713,248 Commitments and Contingencies Total stockholders’ equity 16,840,062 14,484,660 Total liabilities and stockholders' equity $36,627,841 $35,197,908

  • HTG Molecular Diagnostics to Announce Q1 2021 Financial Results and Host Conference Call on Thursday, May 13
    GlobeNewswire

    HTG Molecular Diagnostics to Announce Q1 2021 Financial Results and Host Conference Call on Thursday, May 13

    TUCSON, Ariz., May 04, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the quarter ended March 31, 2021 after the market close on Thursday, May 13, 2021. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time. Conference Call & Webcast Details: Date:Thursday, May 13 Time:4:30 pm Eastern TimeToll Free:877-407-0789International:201-689-8562Conference ID:13719223Webcast:http://public.viavid.com/index.php?id=144644 About HTG: HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine. Contact:Ashley R. RobinsonLifeSci Advisors, LLCPhone: (617) 430-7577Email: arr@lifesciadvisors.com

  • HTG Molecular Diagnostics Reports Preliminary First Quarter 2021 Financial Results
    GlobeNewswire

    HTG Molecular Diagnostics Reports Preliminary First Quarter 2021 Financial Results

    TUCSON, Ariz., April 05, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported certain preliminary financial results for the first quarter ended March 31, 2021. As discussed during HTG’s earnings conference call on March 25, the company believes its full year 2021 revenue could grow 30% to 40% over 2020 levels as it navigates a resurgence of COVID-19, which impacted the first quarter and is expected to continue to impact at least the first half of 2021. HTG expects to report unaudited total revenue for the first quarter ended March 31, 2021 of approximately $1.4 million, and cash, cash equivalents and short-term marketable securities of approximately $30.8 million as of March 31, 2021. “After seeing many of our customers begin to return to work in the fourth quarter of 2020, we were cautiously optimistic that we were starting to pull out of the COVID-19-related revenue impact that we experienced throughout most of 2020. However, a second round of COVID-19-related closures, especially in Europe, have again impacted our core business, delaying planned studies and product sales,” said John Lubniewski, CEO of HTG. “While we remain confident in the main drivers and underlying demand for our products, and still believe that full year 2021 revenue could grow 30% to 40% over 2020 levels, we believe regional and company level closures will continue to add turbulence to our revenue recovery throughout the first half of 2021.” Mr. Lubniewski continued, “We continue to see a fundamental macro trend of personalized medicine driving an increased use of biomarkers, especially RNA-based biomarkers. We believe our technology continues to be an ideal tool to address deployable alternatives for measuring gene expression, advance clinical trials, and lower false discovery rates in preclinical screening. We plan to continue to focus on diversifying our customer base and further expanding into markets outside of oncology for sales of existing HTG EdgeSeq products. In addition, we are in the final development phase of our planned transcriptome panel and the related Early Adopter Program, which we believe will move us toward our planned commercial launch in the third quarter of 2021.” The preliminary results set forth above are based on management’s initial review of the company’s results as of and for the quarter ended March 31, 2021 and are subject to revision based upon the company’s quarter-end closing procedures and the completion and review by the company’s external auditors of the company’s quarter-end financial statements. Actual results may differ materially from these preliminary results as a result of the completion of quarter-end closing procedures, final adjustments, and other developments arising between now and the time that the company’s financial results are finalized. In addition, these preliminary results are not a comprehensive statement of the company’s financial results for the quarter ended March 31, 2021, should not be viewed as a substitute for complete financial statements prepared in accordance with generally accepted accounting principles, and are not necessarily indicative of the company’s results for any future period. The company expects to announce full March 31, 2021 financial results in advance of its quarterly conference call in May 2021. About HTG:HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine. Safe Harbor Statement: Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our expected revenue and other expected financial results as of and for the three months ended March 31, 2021, and regarding our intention to develop and launch a transcriptome product, the anticipated benefits of our planned transcriptome panel Early Access Program, the impact of strategic adjustments made to lessen the impact of COVID-19, our belief that revenue will begin to recover to pre-COVID levels at some point in 2021, and the expected timing of the commercial launch of our transcriptome panel. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that our actual revenue or other financial results for the quarter ended March 31, 2021 may differ materially from those set forth in this press release as a result of the completion of quarter-end closing procedures, risks associated with the impact of the COVID-19 pandemic on us and our customers; the risk that our transcriptome panel may not provide the benefits that we expect; risks associated with our ability to develop and commercialize our products, including our transcriptome panel; the risk that our products and services may not be adopted by biopharmaceutical companies or other customers as anticipated, or at all; our ability to manufacture our products to meet demand; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Annual Report on Form 10-K for the year ended December 31, 2020. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Contact: Ashley RobinsonPhone: (617) 430-7577Email: arr@lifesciadvisors.com